moderna has no case accrual for first planned interim analysis of its mrna vaccine against covid-19
moderna has no case accrual for first planned interim analysis of its mrna vaccine against covid-19
about mrna-1273 mrna-1273 is an mrna vaccine against covid-19 encoding for a prefusion stabilized form of the spike (s) protein, which was co-developed by moderna and investigators from niaids vaccine research center.", "the first clinical batch, which was funded by the coalition for epidemic preparedness innovations, was completed on february 7, 2020 and underwent analytical testing; it was shipped to the nih on february 24, 42 days from sequence selection.")